Find Faculty
Home>Find Faculty>Beverly E. Sha, MD

Beverly E. Sha, MD

Doctor Beverly Sha
Director, Mark Weiss Memorial Clinic for Infectious Diseases
Professor, Department of Internal Medicine, Division of Infectious Diseases, RUSH Medical College
Education

MD, Johns Hopkins University School of Medicine
Internal Medicine Residency, Rush Medical College
Infectious Disease Fellowship, Rush Medical College

Research Areas

Sha has been an investigator with the AIDS Clinical Trials Group (ACTG) since 1989 and the Women’s Interagency HIV Study (WIHS) since 1994. She has extensive experience in running a clinical research site and overseeing the day-to-day activities of the Rush Clinical Research Site. She has been the principal investigator for the Rush WIHS site since 1998.  

Areas of Expertise:

Sha has devoted her career to advancing the treatment and understanding of HIV. She has a special interest in HIV in women, genital tract inflammation, and expanding HIV testing and linkage to care. 

Contact Info:

600 S. Paulina St.
Suite 140
Chicago, IL 60612
Phone: (312) 942-5865
Fax: (312) 942-8200
beverly_e_sha@rush.edu
Links:
Honors and Activities

2017
The POZ 100, recognizing women committed to ending the HIV epidemic

2008-2018
Chicago Magazine Top Doctors
Infectious Diseases
Castle Connolly Medical, LTD

2007
2007 Outstanding Health Care Advocate Award
AIDS Legal Council of Chicago

2003-04
Rush University Medical Center
Chicago, IL
Recipient of the Department of Internal Medicine Teaching   
and Service Award

1993-94
Rush-Presbyterian-St. Luke’s Medical Center
Chicago, IL
Recipient of the Department of Internal Medicine Teaching  
and Service Award

Publications

Manuscripts:

  1. O’Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC et al for the COVID-19 Phase 3 Prevention Trial Team.  Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection:  A randomized clinical trial.  JAMA 2022;327(5):432-441. PMID 35029629.  *collaborator 
  2. Sobieszczyk ME, Maaske J, Falsey AR, Sproule S, Robb ML, Frenck Jr. RW et al for the AstraZeneca Clinical Study Group.  Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months.  J Clin Invest 2022;132(18):e160565. https://doi.org/10.1172/JCI160565. *collaborator
  3. Melani RD, Des Soye BJ, Kafader JO, Forte E, Hollas M, Blagojevic V, Negrao F, McGee JP, Drown B, Lloyd-Jones C, Seckler HS, Camarillo JM, Compton PD, LeDuc RD, Early B, Fellers RT, Cho BK, Mattamana BB, Goo YA, Thomas PM, Ash MK, Bhimalli PP, Al-Harthi L, Sha BE, Schneider JR, Kelleher NL Next generation serology by mass spectrometry:  Readout of the SARS-CoV-2 antibody repertoire.  J Proteome Res 2022;21(1):274-88.  PMID 34268518, PMCID PMC8282107.  https://doi.org/10.1021/acs.jproteome.1c00882
  4. Keizur E, Robinson E, Sha BE, Aziz M, Shankaran S.  Effectiveness of an electronic health record model for HIV pre-exposure prophylaxis.  Int’l J of STD & AIDS 2022 Apr;33(5):499-502.  Doi:10.1177/09564624221079070. Epub 2022 Feb 27. PMID: 35225082.
  5. Barbian HJ, Meaton MS, Narasipura Sd, Wallace J, Rajan R, Sha BE, Al-Harthi L. b-catenin regulates HIV latency and modulates HIV reactivation.  PLoS Pathog 2022;18(3):e1010354.  PMID 35255110, PMCID PMC8939789.  https://doi.org/10.1371/journal.ppat.1010354
  6. Schnittman SR, Lu MT, Mayrhofer T, Burdo T, Fitch KV, McCallum S, Fulda ES, Zanni MV, Foldyna B, Malvestutto C, Fichtenbaum C, Aberg JA, Bloomfield G, Overton T, Currier J, Tebas P, Sha BE, Ribaudo HJ, Flynn JM, Douglas PS, Erlandson KM, Grinspoon SK.  Cytomegalovirus immunoglobulin G (IgG) titer and coronary artery disease in people with human immunodeficiency virus (HIV).  Clin Infec Dis 2022;ciac662, https://doi.org/10.1093/cid/ciac662
  7. Whitney E, Pitrak D, Beavis KG, Moore NM, Shankaran S, Precy Abeleda A, Schmitt J, Sha BE.  Utility of the Signal to Cutoff Ratio and Antigen Index from 4th and 5th Generation HIV-1,2 Antigen/Antibody (Ag/Ab) Assays for the Diagnosis of Acute HIV Infection:  Applicability for Real-Time Use for Immediate Initiation of Antiretroviral Therapy (ART).  J Clin Micro 2022.  https://doi.org/10.1128/jcm.01204-22.
  8. Forte E, Des Soye BJ, Melani RD, Hollas MAR, Kafader JO, Sha BE, Schneider JR, Kelleher ML.  Divergent antibody repertoires found for Omicron versus Wuhan SARS-CoV-2 strains using Ig-MS.  J Proteome Res 2022.  https://doi.org/10.1021/acs.jproteome.2c00514.  
  9. Ash MK, Bhimalli PP, Cho BK, Mattamana BB, Gambut S, Tarhoi I, Fhied CL, Reyes AF, Arivalagan J, Negrao F, Goel R, Beck TL, Hope TJ, Sha BE, Goo YA, Al-Harthi L, Mamede JI, Borgia JA, Kelleher NL, Schneider JR.  Bulk IgG glycosylation predicts COVID-19 severity and vaccine antibody responses.  Cell Reports 2022, https://doi.org/10.1016/j.celrep.2022.111799
  10. Mena Lora AJ, Long, JE, Huang Y, Baden LR, El Sahly HM, Follmann D et al.  Rapid development of an integrated network infrastructure to conduct phase 3 Covid-19 vaccine trials.  JAMA Network 2022 (accepted).  *collaborator

Abstracts:

  1. Ash M, Bhimalli P, Cho BK, Mattamana BB, Gambut S, Tarhoni I, Fhied C, Hope T, Sha B, Goo YA, Al-Harthi L, Mamede J, Borgia J, Kelleher N, Schneider J.  IgG glycosylation predicts COVID-19 disease severity and vaccine antibody response.  Conference on Retroviruses and Opportunistic Infections, February 12-16, 2022.  Denver, CO.  Abstract #255.
  2. Keizur E, Robinson E, Sha BE, Aziz M, Shankaran S.  Effectiveness of an electronic health record model for HIV pre-exposure prophylaxis.  Rush University Medical Center Trainee Research Day. March 17, 2022, Chicago, IL.  Abstract #92.
  3. Rhee Y, Hayden MK, Schoeny M, Fukuda C, Bell P, Simms A, Sha BE, Santos CAQ, Lin M.  Indwelling medical devices and skin microorganisms on intensive care unit patients bathed with chlorhexidine gluconate.  SHEA Spring Conference, April 12-14, 2022.  Colorado Springs, CO.  Abstract #314
  4. Swanson PA, Padilla M, Falsey AR, Sobieszczyk ME, Luetkemeyer AF, Paulsen GC, Riddler SA, Rolle CP, Sha BE, Bansal H, Durham NM, Maaske J, Shoemaker K, Sproule S, Villafana T, Kelly EJ.  Analysis of initial cellular immune responses to breakthrough SARS-CoV-2 infection following primary series AZD12222 (ChAdOx1 nCoV-19) vaccination.  OPTIONS XI for the Control of Influenza, September 26-29, 2022. Belfast, UK Abstract #P-362.
  5. Sobieszczyk ME, Falsey AR, Luetkemeyer AF, Paulsen GC, Riddler SA, Robb ML, Rolle CP, Sha BE, Tong T, Ahani B, Aksyuk AA, Bansal H, Green JA, Jepson B, Maaske J, Shoemaker K, Sproule S, Stanley, AM, Wilkins D, Villafana T, Kelly EJ.  Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCOV-19) vaccination.  IDWeek October 19-23, 2022.  Washington, DC. Abstract #1953
  6. Swanson PA, Padilla M, Falsey AR, Sobieszczyk ME, Luetkemeyer AF, Paulsen GC, Riddler SA, Rolle CP, Sha BE, Bansal H, Durham NM, Maaske J, Shoemaker K, Sproule S, Villafana T, Kelly EJ.  Analysis of initial cellular immune responses to breakthrough SARS-CoV-2 infection following primary series AZD12222 (ChAdOx1 nCoV-19) vaccination.  OPTIONS XI for the Control of Influenza, September 26-29, 2022. Belfast, UK Abstract #P-362.
  7. Friedman E, Shankaran S, Devlin S, Kishen E, Mason JA, Sha BE, Ridgway J.  Development of a predictive model for identifying PrEP-eligible women.  17th International Conference on HIV Treatment and Prevention Adherence, November 7-9, 2022, Washington, DC.  Abstract #1177.
  8. McBroom J, Rana A, Holstad M, Cimiotti J, Higgins M, Knittel A, Kassaye S, Sha B, Hanna D, D’Souza G, Fischl M, Gustafson D, Sheth A.  The influence of postpartum retention in care on mortality in women living with HIV.  Association of nurses in AIDS Care, November 17-19, 2022, Tampa, FL.  Abstract A-29. 

PubMed MyBibliography

Grants

Ongoing Research Support

U01AI34993 (Sha) 1/1/18-12/31/18
NIH/NIAID
Women’s Interagency HIV Study
The major goals of this project are to determine the spectrum and course of HIV disease and its complications in women (including specific gynecologic conditions such as vaginal candidiasis).  
Role: Site PI

U01AI069471 (Sha) 12/10/13-12/9/20
NIH/NIAID
Adult AIDS Clinical Trials Grant-Rush 2702 CRS
The major goals of this project are to provide an effective and efficient system to evaluate the safety and efficacy of therapeutic interventions against HIV infections, AIDS and its associated conditions; to ensure that studies developed by the ACTG Investigators address questions of the highest scientific priority, to assist in the development of new agents and to set standards for patient care. 
Role: Site PI.  

Gilead Focus 1/1/15-7/31/19
Gilead Sciences, Inc
The goal of this project is to increase HIV and HCV testing in our emergency department and primary care outpatient clinics.  

Expanded HIV Testing & Linkage to Care  1/1/18-12/31/18
University of Chicago
The goal of this project is to increase HIV testing at Rush University Medical Center and improve linkage to care of HIV-infected persons.